Retrograde trafficking inhibitor of Shiga toxins reduces morbidity and mortality of mice infected with enterohemorrhagic Escherichia coli

Thomas Secher (1) , Ayaka Shima (2) , Karen Hinsinger (3) , Jean Christophe Cintrat (3) , Ludger Johannes (4) , Julien Barbier (3) , Daniel Gillet (3) , Eric Oswald (1, 5)

1 INSERM U563 - CNRS UMR1037 - Centre de Physiopathologie de Toulouse-Purpan
2 CPTP - Centre de Physiopathologie Toulouse Purpan
3 CEA - Commissariat à l'énergie atomique et aux énergies alternatives
4 CBMCT - UMR 3666 / U1143 - Chimie biologique des membranes et ciblage thérapeutique
5 Service Bactériologie et hygiène [CHU Toulouse]

The most deadly outbreak of Escherichia coli O104:H4 occurred in Europe in 2011. Here, we evaluated the effects of the retrograde trafficking inhibitor Retro-2cycl in a murine model of E. coli O104: H4 infection. Systemic treatment with Retro-2cycl significantly reduced body weight loss and improved clinical scores and survival rates for O104: H4-infected mice. The present data established that Retro-2cycl contributes to the protection of mice against O104: H4 infection and may represent a novel approach to limit Shiga toxin-producing Escherichia coli (STEC)-induced toxicity.

Domaines: Sciences du Vivant [q-bio]

Thomas Secher, Ayaka Shima, Karen Hinsinger, Jean Christophe Cintrat, Ludger Johannes, et al.. Retrograde trafficking inhibitor of Shiga toxins reduces morbidity and mortality of mice infected with enterohemorrhagic Escherichia coli. Antimicrobial Agents and Chemotherapy, 2015, 59 (8), pp.5010-5013. ⟨10.1128/AAC.00455-15⟩. ⟨hal-02640796⟩